FULL YEAR 2021 RESULTS WEBCAST AND CONFERENCE CALL

April 28, 2022

IMPORTANT NOTICE AND DISCLAIMER

This document has been prepared by Vivoryon Therapeutics N.V. (the "Company" or "We") strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities in the Company or any other entity. By reviewing this document, you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you and will not use this information in relation to any investment decision.

This document and its contents are strictly confidential and may not be reproduced, redistributed, published or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. Failure to comply with these restrictions may constitute a violation of applicable securities laws. Certain information contained in this document is non-public, proprietary and highly confidential information. Accordingly, by accepting and reading this document, you will be deemed to agree not to disclose, reproduce or otherwise distribute any information contained herein.

Certain information contained in this document has been obtained from published and non-published sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, none of the Company or its affiliates, directors, officers, employees, members, partners, shareholders or agents make any representation or warranty with respect to or assume any responsibility for the accuracy of such information, and such information has not been independently verified by the Company.

Certain statements contained in this document constitute forward-looking statements, estimates, predictions, influences and projections which are subject to risks and uncertainties and may reflect various assumptions, which may or may not prove to be correct. These forward-looking statements include information about possible or assumed future results of the Company's business, financial condition, results of operations, liquidity, plans and objectives. In particular, the words "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate" and "potential," or other similar expressions are intended to identify forward-looking statements. Forward-looking statements appear in a number of places in this presentation and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various risk factors and uncertainties including without limitation in relation to: the effectiveness of our main product candidate, and our ability to commercialize it if the regulatory approval is obtained; our ability to explore benefits of combination therapies between our product candidates and other products; our ability to compete and conduct our business in the future; our ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of our business; our ability to expend our limited resources and to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs. Moreover, we operate in an evolving environment. Thus, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events or otherwise, except as required by applicable law.

VIVORYON'S APPROACH TO OVERCOMING THE CHALLENGES OF AD DRUG DEVELOPMENT

Oral small molecule inhibitor varoglutamstat targeting multiple hallmarks of AD

QPCT/L AS KEY TARGET IN AD

- High unmet medical need in AD despite recent advances
  - Despite approval in the U.S., Aducanumab is not broadly available to patients outside the clinical study setting
  - Uncertainties around regulatory path to approval for other Abeta-antibody-based approaches
- Varoglutamstat is designed as an alternative to overcome challenges of AD drug development
  - Phase 2b-stage oral small molecule with unique, dual mode of action that is truly differentiated from the other approaches in clinical development
  - Prevents formation of toxic Abeta species upstream of other approaches, thereby also targeting tau pathology, neuroinflammation and synaptic impairment
  - Development strategy rooted in promising Ph 1 and Ph 2a results (well-tolerated, statistically significant changes in working memory after only 3 months of treatment)
  - Protected by strong patent estate

VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS



2021 CLINICAL PORTFOLIO HIGHLIGHTS

- **Fast Track designation** granted by the U.S. Food and Drug Administration (FDA) **for varoglutamstat** as an investigational oral small molecule medicine for the potential treatment of early AD
- **VIVA-MIND U.S. Ph 2a/b study** of varoglutamstat initiated and currently enrolling patients into the Ph 2a adaptive dose finding part; coordinated by ADCS and on track for interim futility analysis planned for H1/2023
- **VIVIAD European Ph 2b study** of varoglutamstat ongoing and consistently meeting recruitment objectives, with number of study sites more than doubled to balance the effects of the ongoing pandemic; on track for interim safety analysis planned for mid-2022
- Preclinical evidence published supporting rationale for evaluating **varoglutamstat in combination with monoclonal Abeta** antibodies to treat AD (Hoffmann et al., *Int. J. Mol. Sci. 2021*, 22(21), 11791; https://doi.org/10.3390/ijms222111791)
- **Expansion of manufacturing capabilities for API production** to ensure sustainable study drug supply with varoglutamstat for ongoing and future studies, also increasing flexibility to react to global challenges such as the ongoing pandemic
- **Clinical Trial Application** submitted by partner Simcere **for the development of varoglutamstat in Greater China approved** by China's Center for Drug Evaluation (CDE); Simcere intends to start clinical development in China in H1/2022

2021 CORPORATE DEVELOPMENT HIGHLIGHTS

- **Strategic regional licensing partnership with Simcere** to develop and commercialize N3pE amyloid-targeting medicines to treat AD in Greater China; Vivoryon to receive combined upfront and milestone payments of up to US$ 565 million plus double-digit royalties on sales
- Extraordinary General Meeting **re-appointed Dr. Ulrich Dauer as CEO and appointed Florian Schmid as CFO** (March 2021); Ordinary Annual General Meeting **re-appointed Dr. Michael Schaeffer as CBO**, all items presented for resolution by the Board of Directors approved with large majority (June 2021)
- Significant **expansion of patent portfolio** with a total of 55 additional patents granted in 2021 for Vivoryon's small molecule inhibitors and antibody-based medicines in development to treat AD and other diseases with exceptionally high medical need
- Vivoryon **plans to expand and diversify its Non-Executive Board**, intending to propose two additional candidates for nomination at its 2022 Annual General Meeting to be held later this year, in line with the Company's efforts to meet international best practice standards (post-period)
- **EUR 21 million raised in successful private placement** to support ongoing clinical development; capital raise supported by a number of high-quality institutional investors from Europe and the U.S. as well as members of Vivoryon's Executive and Non-Executive Boards (post-period, April 1, 2022)

CLINICAL DEVELOPMENT STRATEGY

Clear Path To Potential Regulatory Approval
Extensive Phase 1 and Phase 2 trials

Preclinical research
In vitro and in vivo studies

COMPLETED

- QPCT inhibition improves cognitive parameters in AD mouse models
- QPCT is essential for N3pE amyloid and pE-CCL2 formation *in vivo*

Phase 1
Assessment of safety and tolerability in 205 healthy volunteers

COMPLETED

- Varoglutamstat is well-tolerated – no DLT at 800mg twice daily or up to 3.6g once daily

Phase 1
Assessment of safety and tolerability in 60 healthy Chinese volunteers

Planned H1/2022

Phase 2a SAPHIR
Assessment of safety and tolerability in 120 patients with early AD

COMPLETED

- Statistically significant changes from baseline in working memory after only 3 months of treatment (as measured by CogState)
- High target occupancy detected at doses of 150 mg BID and above

Phase 2b VIVIAD
Assessment of safety, tolerability and efficacy in 250 Patients MCI and mild AD

Interim safety readout mid-22; final readout H2/2023

- Endpoints: safety, attention/working memory, NTB, biomarkers

Phase 2a/b VIVA-MIND
Assessment of efficacy and safety in 414 patients with early AD

Stage-gate to Ph2b H1/2023

- Endpoints: safety, attention/working memory, CDR-SB, biomarkers

Pivotal study or accelerated approval

- FDA Fast Track designation granted in 2021
- Two possible scenarios for late-stage development
  - Application for accelerated approval (based on consistent/ positive data of Phase 2b studies)
  - Phase 3 clinical development

BID: twice daily; CDR-SB: clinical dementia rating scale-sum of boxes; DLT: dose-limiting toxicity; NTB: neuropsychological test battery

VAROGLUTAMSTAT CLINICAL MILESTONES

2022/2023 outlook

Viviad

Phase 2b study in 250 patients with MCI/mild AD

Endpoints: safety, attention/working memory, NTB, biomarkers

- 22 sites in 5 countries active
  - No pandemic-related delays
- >90 patients randomized 1:1:1 (placebo/ 300 mg / 600 mg, all BID)
  - On track for interim safety analysis
  - >90 patients to be included in DSMB decision

MID-22 INTERIM SAFETY AND DSMB DECISION
safety/final dose selection

- All patients randomized 1:1 (placebo/ final dose)
  - On track for final readout in H2/2023

VIVA MIND

Phase 2a/b study in 414 patients with early AD

Endpoints: safety, ABC scores/ cognition & EEG , CDR-SB, biomarkers

- Run by ADCS, supported by NIH grant
  - Significant support and visibility
- FDA Fast Track designation
  - Opportunity to benefit from more frequent engagement with the FDA
- Ph 2a part ongoing with 11 active sites
  - Randomizing and treating patients despite pandemic and weather-related challenges in the U.S.
  - On track for interim futility analysis

H1/2023 STAGE GATE DECISION
safety/efficacy, transition to Ph 2b

Simcere

- Clinical Trial Application approved in China
- Ph 1 study planned for H1/2022, Ph2 to follow

Several key milestones in 2022/23; overall data set intended to support clear path to approval

CONDENSED STATEMENT OF PROFIT AND LOSS

In €k	2021	2020	%
Gross profit	9,196	0	
Research and development expenses	(17,452)	(13,210)	32 %
General and administrative expenses	(4,549)	(2,807)	62 %
Operating loss	(12,798)	(16,011)	(20) %
Finance result	575	(499)	>100%
Income taxes	(432)	0	
Net loss for period	(12,655)	(16,510)	(23) %
Loss per share (basic and diluted) (in EUR)	(0.63)	(0.83)	

KEY FINANCIAL FIGURES

In €k	Dec 31, 2021	Dec 31, 2020
Cash and cash equivalents	14,661	26,306
Total assets	24,520	29,751
Total equity	16,557	26,221
Shares (number)	20,050,482	19,975,482

In €k	2021	2020
Cash flows used in operating activities	(11,257)	(14,012)
Cash flows used in investing activities	(28)	(640)
Cash flows used in by financing activities	(827)	(90)
Cash and cash equivalents at the end of period	14,661	26,306



Q&A



Vivoryon Therapeutics N.V.

Munich
Franz-Josef-Delonge-Str. 5
81249 München
Germany

Halle (Saale)
Weinbergweg 22
06120 Halle (Saale)
Germany

info@vivoryon.com
+49 (0)345 555 99 00

www.vivoryon.com